Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: A multicentre study

European Respiratory Journal

Volumn 49, Issue 5, 2017, Pages

  Borisov, Sergey E ^a   Dheda, Keertan ^b   Enwerem, Martin ^c   Leyet, Rodolfo Romero ^d   D'Ambrosio, Lia ^e,f   Centis, Rosella ^e   Sotgiu, Giovanni ^g   Tiberi, Simon ^h,i   Alffenaar, Jan Willem ^j   Maryandyshev, Andrey ^k   Belilovski, Evgeny ^a   Ganatra, Shashank ^l   Skrahina, Alena ^m   Akkerman, Onno ^j   Aleksa, Alena ⁿ   Amale, Rohit ^l   Artsukevich, Janina ⁿ   Bruchfeld, Judith ^o   Caminero, Jose A ^p,q   Martinez, Isabel Carpena ^r   Codecasa, Luigi ^s   Dalcolmo, Margareth ^t   Denholm, Justin ^u   Douglas, Paul ^v   Duarte, Raquel ^w   Esmail, Aliasgar ^b   Fadul, Mohammed ^b   Filippov, Alexey ^a   Forsman, Lina Davies ^o   Gaga, Mina ^x   Garcia Fuertes, Julia Amaranta ^y   García García, José María ^z   Gualano, Gina ^aa   Jonsson, Jerker ^ab   Kunst, Heinke ⁱ   Lau, Jillian S ^ac   Mastrapa, Barbara Lazaro ^ad   Troya, Jorge Lazaro Teran ^ad   Manga, Selene ^ae   Manika, Katerina ^af   Montaner, Pablo González ^ag   Mullerpattan, Jai ^l   Oelofse, Suzette ^b   Ortelli, Martina ^ah   Palmero, Domingo Juan ^ag   Palmieri, Fabrizio ^aa   Papalia, Antonella ^ai   Papavasileiou, Apostolos ^x   Payen, Marie Christine ^aj   Pontali, Emanuele ^ak   Cordeiro, Carlos Robalo ^al   Saderi, Laura ^g   Sadutshang, Tsetan Dorji ^am   Sanukevich, Tatsiana ⁿ   Solodovnikova, Varvara ^m   Spanevello, Antonio ^ah,an   Topgyal, Sonam ^am   Toscanini, Federica ^ao   Tramontana, Adrian R ^ap   Udwadia, Zarir Farokh ^l   Viggiani, Pietro ^ai   White, Veronica ^aq   Zumla, Alimuddin ^ar   Migliori, Giovanni Battista ^e   more..

^a Moscow Research and Clinical Center for Neuropsychiatry   (Russian Federation)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Amity Health Consortium   (South Africa)

^d Clinical Unit   (South Africa)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f Public Health Consulting Group SAGL   (Switzerland)

^g UNIVERSITY OF SASSARI   (Italy)

^h ROYAL LONDON HOSPITAL   (United Kingdom)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k NORTHERN STATE MEDICAL UNIVERSITY   (Russian Federation)

^l P D HINDUJA NATIONAL HOSPITAL   (India)

^m Republican Scientific and Practical Center for Pulmonology and Tuberculosis   (Belarus)

ⁿ GRODNO STATE MEDICAL UNIVERSITY   (Belarus)

^o KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^p HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^q INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^r HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^s OSPEDALE NIGUARDA CA GRANDA   (Italy)

^t INSTITUTO OSWALDO CRUZ   (Brazil)

^u UNIVERSITY OF MELBOURNE   (Australia)

^v Fiocruz/MoH ^*  (Australia)

^w University of Porto   (Portugal)

^x Athens Chest Hospital   (Greece)

^y HOSPITAL TXAGORRITXU   (Spain)

^z Tuberculosis Research Programme   (Spain)

^aa NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^ab SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^ac BOX HILL HOSPITAL   (Australia)

^ad Harry Surtie Hospital   (South Africa)

^ae UNIVERSIDAD NACIONAL DE SAN ANTONIO ABAD DEL CUSCO   (Peru)

^af ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^ag HOSPITAL F J MUÑIZ   (Argentina)

^ah UNIVERSITY OF INSUBRIA   (Italy)

^ai Reference Hospital for MDR and HIV TB   (Italy)

^aj SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^ak GALLIERA HOSPITAL   (Italy)

^al CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^am Delek Hospital   (India)

^an IRCCS   (Italy)

^ao UNIVERSITY OF GENOA   (Italy)

^ap Western Hospital   (Australia)

^aq BARTS HEALTH NHS TRUST   (United Kingdom)

^ar UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; CARBAPENEM; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; STREPTOMYCIN; CARBAPENEM DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BACTERIUM CULTURE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HALLUCINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; KIDNEY FAILURE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; OPTIC NERVE DISEASE; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QT PROLONGATION; RASH; RETROSPECTIVE STUDY; SPUTUM SMEAR; TENDINITIS; THROMBOCYTOPENIA; VESTIBULAR DISORDER; VOMITING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; METABOLISM; MIDDLE AGED; PATIENT SAFETY; SPUTUM; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; CARBAPENEMS; CLOFAZIMINE; COHORT STUDIES; DIARYLQUINOLINES; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HIV INFECTIONS; HUMANS; LINEZOLID; MALE; MIDDLE AGED; PATIENT SAFETY; RETROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85026222831     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00387-2017     Document Type: Article

References (46)

1. World Health Organization. Global Tuberculosis Report 2016. WHO/HTM/TB/2016.13 Geneva, World Health Organization, 2016.
2. Falzon D, Linh Nhat N, Jaramillo E, et al. The global response to rifampicin-resistant tuberculosis: current situation and recent trends. Eur Respir J 2016; 48: Suppl. 60, PA1903.
3. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
4. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
5. Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
6. Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One 2013; 8: e63057.
7. Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 2015; 45: 25-29.
8. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015; 45: 161-170.
9. Lee M, Cho SN, Barry CE 3rd, et al. Linezolid for XDR-TB-final study outcomes. N Engl J Med 2015; 373: 290-291.
10. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402.
11. Pontali E, D'Ambrosio L, Centis R, et al. Multidrug-resistance tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. Eur Respir J 2017; 49: 1700146.
12. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
13. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
14. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
15. Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564-574.
16. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
17. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
18. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
19. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979-985.
20. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
21. Guglielmetti L, Jaspard M, Le Dû D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1601799.
22. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. Eur Respir J 2016; 47: 664-667.
23. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
24. Sotgiu G, Centis R, D'Ambrosio L, et al. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290.
25. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
26. Sotgiu G, Centis R, D'Ambrosio L, et al. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur Respir J 2015; 45: 287-289.
27. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J 2016; 47: 333-336.
28. van Rijn SP, van Altena R, Akkerman OW, et al. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. Eur Respir J 2016; 47: 1229-1234.
29. Tiberi S, Payen MC, Sotgiu G, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR-and XDR-TB. Eur Respir J 2016; 47: 1235-1243.
30. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2016; 62: 1188-1190.
31. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR-and XDR-TB. Eur Respir J 2016; 47: 1758-1766.
32. Dalcolmo M, Gayoso R, Sotgiu G, et al. Effectiveness and safety of clofazimine within a standard multidrugresistant tuberculosis regimen in Brazil: first nation-wide report on over 2,500 cases. Eur Respir J 2017; 49: 1602445.
33. Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015; 60: 1361-1367.
34. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
35. Winters N, Butler-Laporte G, Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur Respir J 2015; 46: 1461-1470.
36. Alsaad N, Wilffert B, van Altena R, et al. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J 2014; 43: 884-897.
37. Udwadia ZF, Amale RA, Mullerpattan JB. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Int J Tuberc Lung Dis 2014; 18: 1315-1318.
38. Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016; 48: 935-938.
39. Wallis RS. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 2016; 48: 1526-1527.
40. Tadolini M, Lingtsang RD, Tiberi S, et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 2016; 48: 1527-1529.
41. Rendon A, Fuentes Z, Torres-Duque CA, et al. Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance. Eur Respir J 2016; 48: 1282-1287.
42. Dalcolmo M, Gayoso R, Sotgiu G, et al. Resistance profile to the drugs composing the 'shorter' regimen for multidrug-resistant TB in Brazil, 2000-2015. Eur Respir J 2017; 49: 1602309.
43. Ndjeka N, the Bedaquiline Clinical Access Programme, the Bedaquiline Implementers of the South African National TB Programme. Incorporation of Bedaquiline in the South African National TB Programme. 23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), February 22-25, 2016, Boston. Abstract #754.
44. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2006.
45. World Health Organization. Active Tuberculosis Drug-Safety Monitoring and Management (aDSM): Framework for Implementation. WHO/HTM/TB/2015.28. Geneva, World Health Organization, 2015.
46. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.